Hologic has reportedly turned down acquisition offers from private equity firms TPG and Blackstone, who valued the women’s health and diagnostics giant at over $16 billion, according to Financial Times.
While the Marlborough, MA-based company declined the bid, sources say the deal could resurface. Hologic faces potential headwinds, including manufacturing tariffs in China and Costa Rica and reduced demand—factors that recently led to lowered profit projections.
The news caused Hologic’s stock to surge nearly 20%, with shares up another 2.3% to $63.65.
Private equity remains active in medtech, with past moves involving Medtronic, J&J, Baxter, and others. Hologic, generating over $4B annually, ranks as the 30th largest medtech company globally.
Follow MEDWIRE.AI for the latest in medtech M&A trends.
